Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials

References

• A., S. 2013. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39:197–208. doi:10.1002/biof.1062.
   PubMed Web of Science ®Google Scholar
• A., S. 2014. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 28:633–642. doi:10.1002/ptr.5045.
   PubMed Web of Science ®Google Scholar
• Alwi I, S. T., S. Suyono, B. Sutrisna, F. D. Suyatna, S. B. Kresno, and S. Ernie. 2008. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 40:201–210.
   PubMedGoogle Scholar
• Anand P, K. A., R. A. Newman, and B. B. Aggarwal. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818. doi:10.1021/mp700113r.
   PubMed Web of Science ®Google Scholar
• Arca M, M. A., S. Valiante, F. Campagna, G. Pigna, V. Paoletti, R. Antonini, F. Barillà, G. Tanzilli, A. Vestri, and C. Gaudio. 2007. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol 100:1511–1516. doi:10.1016/j.amjcard.2007.06.049.
   PubMed Web of Science ®Google Scholar
• Baigent C, K. A., P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes; Cholesterol Treatment Trialists' (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Baum L, C. S., V. C. Mok, L. C. Lam, V. P. Leung, E. Hui, C. C. Ng, M. Chow, P. C. Ho, S. Lam, J. Woo, H. F. Chiu, W. Goggins, B. Zee, A. Wong, H. Mok, W. K. Cheng, C. Fong, J. S. Lee, M. H. Chan, S. S. Szeto, V. W. Lui, J. Tsoh, T. C. Kwok, I. H. Chan, and C. W. Lam. 2007. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 56:509–514. doi:10.1016/j.phrs.2007.09.013.
   PubMed Web of Science ®Google Scholar
• Budoff, M. 2016. Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. The American journal of cardiology Jul 01;118:138–145. doi:10.1016/j.amjcard.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Chapman, M. J., J. S. Redfern, M. E. McGovern, and P. Giral. 2010. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacology & therapeutics Jun;126:314–345. doi:10.1016/j.pharmthera.2010.01.008.
   PubMed Web of Science ®Google Scholar
• Chuengsamarn S, R. S., B. Phonrat, R. Tungtrongchitr, and S. Jirawatnotai. 2014. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem 25:144–150. doi:10.1016/j.jnutbio.2013.09.013.
   PubMed Web of Science ®Google Scholar
• Cox KH, P. A., and A. B. Scholey. 2015. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 29:642–651. doi:10.1177/0269881114552744.
   PubMed Web of Science ®Google Scholar
• DiSilvestro RA, J. E., S. Zhao, and J. Bomser. 2012. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11:79. doi:10.1186/1475-2891-11-79.
   PubMed Web of Science ®Google Scholar
• Duval S, T. R. 2000. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463. doi:10.1111/j.0006-341X.2000.00455.x.
   PubMed Web of Science ®Google Scholar
• Fruchart, J. C., F. Sacks, M. P. Hermans, G. Assmann, W. V. Brown, R. Ceska, M. J. Chapman, P. M. Dodson, P. Fioretto, and H. N. Ginsberg, et al. 2008. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. The American journal of cardiology Nov 17;102:1K–34K. doi:10.1016/j.amjcard.2008.10.002.
   PubMed Web of Science ®Google Scholar
• Funamoto M, S. Y., Y. Katanasaka, Y. Miyazaki, A. Imaizumi, H. Kakeya, H. Yamakage, N. Satoh-Asahara, M. Komiyama, H. Wada, K. Hasegawa, and T. Morimoto. 2016. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD. Int J Chron Obstruct Pulmon Dis 11:2029–2034. doi:10.2147/COPD.S104490.
   PubMed Web of Science ®Google Scholar
• Ganjali, S., C. N. Blesso, M. Banach, M. Pirro, M. Majeed, and A. Sahebkar. 2017. Effects of curcumin on HDL functionality. Pharmacological research Feb 10;119:208–218. doi:10.1016/j.phrs.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Ganjali, S., A. Sahebkar, E. Mahdipour, K. Jamialahmadi, S. Torabi, S. Akhlaghi, G. Ferns, S. M. Parizadeh, and M. Ghayour-Mobarhan. 2014. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. TheScientificWorldJournal 2014:898361. doi:10.1155/2014/898361.
   PubMed Web of Science ®Google Scholar
• Gomaraschi, M., M. P. Adorni, M. Banach, F. Bernini, G. Franceschini, and L. Calabresi. 2015. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. Handbook of experimental pharmacology 224:593–615. doi:10.1007/978-3-319-09665-0_19.
   PubMedGoogle Scholar
• Higgins JPT, G. S., eds. 2009. Cochrane Handbook for Systematic Reviews of Interventions London.
   Google Scholar
• Hozo SP, D. B., and I. Hozo. 2005. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13.
   PubMedGoogle Scholar
• Johnston, T. P., T. A. Korolenko, M. Pirro, and A. Sahebkar. 2017. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacological research Jun;120:219–225.
   PubMed Web of Science ®Google Scholar
• Kocher A, B. L., C. Schiborr, and J. Frank 2016. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res 60:1555–1563.
   PubMed Web of Science ®Google Scholar
• Lamarche, B., S. Rashid, and G. F. Lewis. 1999. HDL metabolism in hypertriglyceridemic states: an overview. Clinica chimica acta; international journal of clinical chemistry Aug;286:145–161.
   PubMed Web of Science ®Google Scholar
• Landray, M. J., Reveal Collaborative G, L. Bowman FCESJCHKWWSEV-MSWCPCEBRC. 2017. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American heart journal May;187:182–190.
   PubMed Web of Science ®Google Scholar
• Maki, K. C., and M. R. Dicklin. 2017. Do triglyceride-lowering drugs decrease risk of cardiovascular disease? Current opinion in lipidology 28 (4):374–379.
   PubMed Web of Science ®Google Scholar
• Manjunatha H, S. K. 2007. Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in induced hypercholesterolemic rats. Lipids 42:1133–1142.
   PubMed Web of Science ®Google Scholar
• Martin RC, A. H., D. Malik, and Y. Li. 2012. Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: Similar root but different effects. Food Chem Toxicol 50:227–231.
   PubMed Web of Science ®Google Scholar
• Marz, W., M. E. Kleber, H. Scharnagl, T. Speer, S. Zewinger, A. Ritsch, K. G. Parhofer, A. von Eckardstein, U. Landmesser, and U. Laufs. 2017. HDL cholesterol: reappraisal of its clinical relevance. Clinical research in cardiology: official journal of the German Cardiac Society Mar 24. doi:10.1007/s00392-017-1106-1. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mirzabeigi P, M. A., M. Salarifar, K. Gholami, M. Mojtahedzadeh, and M. R. Javadi. 2015. The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial. Iran J Pharm Res 14:479–486.
   PubMed Web of Science ®Google Scholar
• Mohammadi A, S. A., M. Iranshahi, M. Amini, R. Khojasteh, M. Ghayour-Mobarhan, and G. A. Ferns. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27:374–379. doi:10.1002/ptr.4715.
   PubMed Web of Science ®Google Scholar
• Moher, D., A. Liberati, J. Tetzlaff, D. G. Altman, and P. Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj Jul 21;339:b2535. doi:10.1136/bmj.b2535.
   PubMed Web of Science ®Google Scholar
• Na LX, L. Y., H. Z. Pan, X. L. Zhou, D. J. Sun, M. Meng, X. X. Li, and C. H. Sun. 2013. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 57:1569–1577. doi:10.1002/mnfr.201200131.
   PubMed Web of Science ®Google Scholar
• Panahi Y, A. G., S. Parvin, and A. Sahebkar. 2016a. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. J Diet Suppl 13:209–220. doi:10.3109/19390211.2015.1008611.
   PubMedGoogle Scholar
• Panahi Y, B. R., G. R. Karami, and A. Sahebkar. 2015a. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29:17–21. doi:10.1002/ptr.5211.
   PubMed Web of Science ®Google Scholar
• Panahi Y, G. M., S. Bashiri, A. Hajihashemi, and A. Sahebkar. 2015b. Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial. Drug Res (Stuttg) 65:567–573.
   PubMed Web of Science ®Google Scholar
• Panahi Y, K. N., M. S. Hosseini, M. Abbasinazari, and A. Sahebkar. 2014a. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22:851–857. doi:10.1016/j.ctim.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Panahi Y, K. N., E. Sahebi, S. Namazi, Z. Reiner, M. Majeed, and A. Sahbekar. 2017. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complement Ther Med 33:1–5. doi:10.1016/j.ctim.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Panahi Y, K. P., R. Mohtashami, R. Jafari, L. E. Simental-Mendía, and A. Sahebkar. 2016b. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J Cardiovasc Pharmacol 68:223–229. doi:10.1097/FJC.0000000000000406.
   PubMed Web of Science ®Google Scholar
• Panahi Y, S. A., M. Amiri, S. M. Davoudi, F. Beiraghdar, S. L. Hoseininejad, and M. Kolivand. 2012. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108:1272–1279. doi:10.1017/S0007114511006544.
   PubMed Web of Science ®Google Scholar
• Panahi Y, S. A., F. Beiraghdar, and A. Sahebkar. 2014b. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 28:1461–1467. doi:10.1002/ptr.5149.
   PubMed Web of Science ®Google Scholar
• Pashine L, S. J., A. K. Vaish, S. K. Ojha, and A. Mehdi. 2012. Effect of turmeric (curcuma longa) on overweight hyperlipidemic subjects: double blind study. Indian J Community Health 24:113–117.
   Google Scholar
• Peschel D, K. R., N. Nass. 2007. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 18:113–119. doi:10.1016/j.jnutbio.2006.03.007.
   PubMed Web of Science ®Google Scholar
• Pirro, M., M. R. Mannarino, V. Bianconi, L. E. Simental-Mendia, F. Bagaglia, E. Mannarino, and A. Sahebkar. 2016. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. Pharmacological research Aug;110:76–88. doi:10.1016/j.phrs.2016.04.021.
   PubMed Web of Science ®Google Scholar
• Pirro, M., C. Vetrani, C. Bianchi, M. R. Mannarino, F. Bernini, and A. A. Rivellese. 2017. Joint position statement on “Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutrition, metabolism, and cardiovascular diseases: NMCD Jan;27:2–17. doi:10.1016/j.numecd.2016.11.122.
   PubMed Web of Science ®Google Scholar
• Pungcharoenkul K, T. P. 2011. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res 25:1721–1726. doi:10.1002/ptr.3608.
   PubMed Web of Science ®Google Scholar
• Rahimi HR, M. A., M. Dastani, M. R. Jaafari, K. Abnous, M. Ghayour Mobarhan, and R. Kazemi Oskuee. 2016. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed 6:567–577.
   PubMed Web of Science ®Google Scholar
• Rahmani S, A. S., G. Askari, M. Keshvari, M. Hatamipour, A. Feizi, and A. Sahebkar. 2016. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res 30:1540–1548. doi:10.1002/ptr.5659.
   PubMed Web of Science ®Google Scholar
• Ramirez Boscá A, S. A., M. A. Carrión-Gutiérrez, D. Pamies Mira, J. Pardo Zapata, J. Diaz-Alperi, A. Bernd, A. E. Quintanilla, and J. Miquel 2000. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev. 114:207–210. doi:10.1016/S0047-6374(00)00089-0.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. 2014. Curcuminoids for the management of hypertriglyceridaemia. Nature reviews Cardiology Feb;11:123. doi:10.1038/nrcardio.2013.140-c1.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, M. A., A. Atabati, S. Rahiman, S. Tavallaie, M. Iranshahi, S. Akhlaghi, G. A. Ferns, and M. Ghayour-Mobarhan 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27:1883–1888. doi:10.1002/ptr.4952.
   PubMed Web of Science ®Google Scholar
• Sampson, U. K., S. Fazio, and M. F. Linton. 2012. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Current atherosclerosis reports Feb;14:1–10. doi:10.1007/s11883-011-0219-7.
   PubMed Web of Science ®Google Scholar
• Shin SK, H. T., R. A. McGregor, and M. S. Choi. 2011. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 55:1829–1840. doi:10.1002/mnfr.201100440.
   PubMed Web of Science ®Google Scholar
• Shishodia S, S. G., B. B. Aggarwal. 2005. Curcumin: getting back to the roots. Ann N Y Acad Sci 1056:206–217. doi:10.1196/annals.1352.010.
   PubMed Web of Science ®Google Scholar
• Sirimarco, G., J. Labreuche, E. Bruckert, L. B. Goldstein, K. M. Fox, P. M. Rothwell, and P. Amarenco, Perform, Investigators S, Committees. 2014. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke May;45:1429–1436. doi:10.1161/STROKEAHA.113.004229.
   PubMed Web of Science ®Google Scholar
• Soudamini KK, U. M., K. B. Soni, and R. Kuttan. 1992. Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J Physiol Pharmacol 36:239–243.
   PubMedGoogle Scholar
• Stone NJ, R. J., A. H. Lichtenstein, C. N. Bairey Merz, C. B. Blum, R. H. Eckel, A. C. Goldberg, D. Gordon, D. Levy, D. M. Lloyd-Jones, P. McBride, J. S. Schwartz, S. T. Shero, S. C. Smith, Jr, K. Watson, P. W. Wilson, K. M. Eddleman, N. M. Jarrett, K. LaBresh, L. Nevo, J. Wnek, J. L. Anderson, J. L. Halperin, N. M. Albert, B. Bozkurt, R. G. Brindis, L. H. Curtis, D. DeMets, J. S. Hochman, R. J. Kovacs, E. M. Ohman, S. J. Pressler, F. W. Sellke, W. K. Shen, S. C. Smith, Jr, and G. F. Tomaselli; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:S1–45. doi:10.1161/01.cir.0000437738.63853.7a.
   PubMed Web of Science ®Google Scholar
• Sukandar EY, S. P., J. I. Sigit, N. P. E. Leliqia, and F. Lestari. 2013. Safety of Garlic (Allium Sativum) and Turmeric (Curcuma domestica) Extract in Comparison with Simvastatin on Improving Lipid Profile in Dyslipidemia Patients. Journal of Medical Sciences 13:10–18. doi:10.3923/jms.2013.10.18.
   Google Scholar
• Taylor F, H. M., A. F. Macedo, T. H. Moore, M. Burke, G. Davey Smith, K. Ward, and S. Ebrahim. 2013. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev.1: CD004816.
   Google Scholar
• Um, M. Y., K. H. Hwang, J. Ahn, and T. Y. Ha. 2013. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic & clinical pharmacology & toxicology Sep;113:152–157. doi:10.1111/bcpt.12076.
   PubMed Web of Science ®Google Scholar
• Usharani P, M. A., M. U. Naidu, Y. S. Raju, and N. Chandra. 2008. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 9:243–250. doi:10.2165/00126839-200809040-00004.
   PubMed Web of Science ®Google Scholar
• Vrecer M, T. S., J. Drinovec, and A. Mrhar. 2003. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 41:567–577. doi:10.5414/CPP41567.
   PubMed Web of Science ®Google Scholar
• Wan X, W. W., J. Liu, and T. Tong. 2014. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. doi:10.1186/1471-2288-14-135.
   PubMed Web of Science ®Google Scholar
• Yang YS, S. Y., H. W. Yang, Y. H. Lee, J. I. Chou, and K. C. Ueng. 2014. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 28:1770–1777. doi:10.1002/ptr.5197.
   PubMed Web of Science ®Google Scholar
• Yusuf S, R. S., S. Ounpuu, and S. Anand. 2001. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104:2746–2753. doi:10.1161/hc4601.099487.
   PubMed Web of Science ®Google Scholar
• Ž., R. 2013. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 10:453–464. doi:10.1038/nrcardio.2013.80.
   PubMed Web of Science ®Google Scholar
• Zingg JM, H. S., and M. Meydani. 2013. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 39:101–121. doi:10.1002/biof.1072.
   PubMed Web of Science ®Google Scholar